Objectives: Oxidized low-density lipoprotein (ox-LDL) may induce autophagy, apoptosis, necrosis or proliferation of cultured endothelial cells depending on the concentration and exposure time. Our previous studies found that ox-LDL exposure for 6 h increases the autophagic level of human umbilical vein endothelial cells (HUVECs) in a concentration-dependent manner. The present study investigates the relationship between autophagy and apoptosis in HUVECs exposed to ox-LDL. Methods: Flow cytometry and Western blot were used to study the apoptotic and autophagic phenomena. The contribution of autophagic and apoptotic mechanisms to ox-LDL-induced upregulation of MAP1-LC3, beclin1 and p53 protein levels were assessed by pretreatment with the autophagic inhibitors 3-MA and Atg5 small interfering (si)RNA, as well as z-vad-fmk, an apoptosis inhibitor. Results: ox-LDL induced the apoptosis of HUVECs in a concentration-dependent way. The increased expression of the autophagic proteins, LC3-II and beclin1, can be reversed by 3-MA and z-vad-fmk pretreatment. 3-MA and Atg5 siRNA increased the ox-LDL-induced increases of the p53 protein level and the annexin V-positive staining, which was decreased by z-vad-fmk. Conclusion: These results suggest that overstimulation of ox-LDL can induce autophagy and apoptosis in HUVECs. Inhibition of apoptosis leads to an inhibition of autophagy induced by ox-LDL. However, inhibition of autophagy leads to an increase in the ox-LDL-induced apoptosis.

1.
Dimmeler S, Haendeler J, Galle J, et al: Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases: a mechanistic clue to the ‘response to injury' hypothesis. Circulation 1997;95:1760-1763.
2.
Trevisi L, Bertoldo A, Agnoletto L, et al: Antiapoptotic and proliferative effects of low concentrations of 7β-hydroxycholesterol in human endothelial cells via ERK activation. J Vasc Res 2010;47:241-251.
3.
Best PJ, Hasdai D, Sangiorgi G, et al: Apoptosis: basic concepts and implications in coronary artery disease. Arterioscler Thromb Vasc Biol 1999;19:14-22.
4.
Pan T, Rawal P, Wu Y, et al: Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience 2009;2164:541-551.
5.
Pan T, Kondo S, Zhu W, et al: Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis 2008;32:16-25.
6.
Du Y, Yang D, Li L, et al: An insight into the mechanistic role of p53-mediated autophagy induction in response to proteasomal inhibition-induced neurotoxicity. Autophagy 2009;5:663-675.
7.
Scarlatti F, Granata R, Meijer AJ, et al: Does autophagy have a license to kill mammalian cells? Cell Death Differ 2009;16:12-20.
8.
Di X, Shiu RP, Newsham IF, et al: Apoptosis, autophagy, accelerated senescence and reactive oxygen in the response of human breast tumor cells to Adriamycin. Biochem Pharmacol 2009;77:1139-1150.
9.
Eisenberg-Lerner A, Bialik S, Simon HU, et al: Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 2009;16:966-975.
10.
Nowicki M, Zabirnyk O, Duerrschmidt N, et al: No upregulation of lectin-like oxidized low-density lipoprotein receptor-1 in serum-deprived EA.hy926 endothelial cells under oxLDL exposure, but increase in autophagy. Eur J Cell Biol 2007;86:605-616.
11.
Harada-Shiba M, Kinoshita M, Kamido H, et al: Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms. J Biol Chem 1998;273:9681-9687.
12.
Zhang YL, Cao YJ, Zhang X, et al: The autophagy-lysosome pathway: a novel mechanism involved in the processing of oxidized LDL in human vascular endothelial cells. Biochem Biophys Res Commun 2010;394:377-382.
13.
Zhang YL, Cao YJ, Yang YP, et al: Autophagy in human umbilical vein endothelial cells involved in atherosclerosis: degradation of ox-LDL. Neurology 2009;72:S398.
14.
Hatch FT: Practical methods for plasma lipoprotein analysis. Adv Lipid Res 1968;6:1-68.
15.
Mizushima N, Yamamoto A, Hatano M, et al: Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J Cell Biol 2001;152:657-668.
16.
Liang XH, Jackson S, Seaman M, et al: Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999;402:672-676.
17.
Gajewska M, Gajkowska B, Motyl T: Apoptosis and autophagy induced by TGF-B1 in bovine mammary epithelial BME-UV1 cells. J Physiol Pharmacol 2005;56:S143-S157.
18.
Wang J: Beclin 1 bridges autophagy, apoptosis and differentiation. Autophagy 2008;4:947-948.
19.
Carew JS, Medina EC, Esquivel JA 2nd, et al: Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med 2010;14:2448-2459.
20.
Chen F, Chen B, Xiao FQ, et al: Autophagy protects against senescence and apoptosis via the RAS-mitochondria in high-glucose-induced endothelial cells. Cell Physiol Biochem 2014;33:1058-1074.
21.
Luo S, Rubinsztein DC: Apoptosis blocks beclin 1-dependent autophagosome synthesis: an effect rescued by Bcl-xL. Cell Death Differ 2010;17:268-277.
22.
Cheng Y, Qiu F, Tashiro S, et al: ERK and JNK mediate TNFα-induced p53 activation in apoptotic and autophagic L929 cell death. Biochem Biophys Res Commun 2008;376:483-488.
23.
Zhang XD, Wang Y, Wang Y, et al: p53 mediates mitochondria dysfunction-triggered autophagy activation and cell death in rat striatum. Autophagy 2009;5:339-350.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.